Marks the eighth advisor to rising KOL program to construct robust physique of scientific proof and help US commercialization
Aclarion to take part in upcoming SPINEWEEK 2023
Broomfield, CO, March 07, 2023 (GLOBE NEWSWIRE) — through NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare expertise firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians establish the situation of continual low again ache, introduced right now that Alpesh Patel, MD, MBA Co-Director of Northwestern Middle for Backbone Health will advise the corporate as a key opinion chief (KOL). Along with his management function within the Middle for Backbone Health, Dr. Patel serves as professor of Orthopaedic Surgical procedure and Neurosurgery at Northwestern College in Evanston, IL.
Persistent low again ache (CLBP) is a world drawback, with an estimated 266 million individuals worldwide struggling degenerative spine illness and low again ache that may result in a discount within the high quality of life. Aclarion’s Nociscan resolution is the primary evidence-supported SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be related to disc ache. Biomarker information is entered into proprietary algorithms to spotlight if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan supplies crucial insights into the situation of a affected person’s low again ache, giving physicians readability to optimize therapy methods.
“All through my profession I’ve centered on cost-effectiveness and worth in spine care, making spine surgical procedure right here at Northwestern, in addition to all through the US and the world, safer and more practical,” mentioned Dr. Patel. “The connection between cost-effectiveness and worth in spine care has fueled my curiosity in really progressive applied sciences. Aclarion’s Nociscan expertise is addressing a big market and a posh drawback – extra deeply and objectively understanding pathology of continual low again ache.”
Dr. Patel is the eighth key opinion chief advisor introduced by Aclarion. “Dr. Patel has established himself as a pacesetter amongst his peer group clinically, economically, and as an educator. The broad perspective he has cultivated will present useful insights to Aclarion and our mission to alter paradigms within the analysis and therapy of continual low again ache,” mentioned Ryan Bond, Chief Technique Officer. “As Co-Director of the Northwestern Middle for Backbone Health, Dr. Patel’s expertise inside one of many United States’ premier built-in well being methods will assist strengthen Aclarion’s place globally within the care supply worth chain.”
As well as, Aclarion will take part in SPINEWEEK 2023, Might 1-5, 2023. For extra details about SPINEWEEK 2023, please go to: https://www.spineweek.org/
About Aclarion, Inc.
Aclarion is a healthcare expertise firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing strategies, biomarkers, and augmented intelligence algorithms to optimize scientific therapies. The Firm is first addressing the continual low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. Via a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) information from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing strategies extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker information is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan supplies crucial insights into the situation of a affected person’s low again ache, giving physicians readability to optimize therapy methods. For extra info, please go to www.aclarion.com.
Ahead Trying Statements
This press launch incorporates forward-looking statements inside the which means of the Personal Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Trade Act of 1934 in regards to the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic information, resembling “anticipates,” “believes” and “expects” or comparable expressions, are forward-looking statements. These forward-looking statements are based mostly on the present plans and expectations of administration and are topic to various uncertainties and dangers that would considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra absolutely in our filings with the Securities and Trade Fee. Readers are inspired to overview the part titled “Threat Components” within the Firm’s Annual Report on Type 10-Okay for the 12 months ended December 31, 2022, in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Trade Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not because of new info, future occasions or in any other case.
Kirin M. Smith
PCG Advisory, Inc.
Discussion about this post